Abstract
Radiofrequency ablation (RFA) is recommended in Japan for patients with hepatocellular carcinomas (HCCs) one to three in number and ≤3 cm in size. The arfa® and VIVA® RFA systems are widely used for patients with HCC and this retrospective observational study aims to compare their performances. The study included 365 patients with HCCs one to three in number and ≤3 cm in size who underwent RFA using the arfa® system (arfa® group) or the VIVA® system (VIVA® group). The total bilirubin (T-Bil) level after RFA was higher in the arfa® group than in the VIVA® group. With a 3-cm electrode needle, the longest diameter (Dmax) and the shortest diameter were analyzed and found to be greater in the arfa® group than in the VIVA® group. Furthermore, Dmax with the 2.5-cm electrode needle was greater in the arfa® group than in the VIVA® group. Statistically significant differences in the ablation area and in the T-Bil value after RFA were observed between the groups; however, these differences are not considered clinical problems because the difference in the ablation area was only slight and the Child–Pugh score was the same between the groups. Thus, hepatologists can use either of the RFA systems based on their preference.
Highlights
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death in the world [1–3]
A statistically significant difference in the etiology of HCC was observed between the arfa® and VIVA® groups (p < 0.05)
We evaluated patients with HCC who underwent Radiofrequency ablation (RFA) in our hospital between April 2016 and November 2021
Summary
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death in the world [1–3]. The medical treatment policy in Japan is based on the consensusbased Clinical Practice Guidelines for HCC Management proposed by the Japan Society of Hepatology (JSH) [4]. Radiofrequency ablation (RFA) or surgical resection is recommended for patients with HCCs one to three in number and ≤3 cm in size [4]. HCC is mainly caused by hepatitis C virus-induced liver cirrhosis [5–7]. Other causes include hepatitis B virus, excessive alcohol consumption, nonalcoholic steatohepatitis, autoimmune hepatitis, and primary biliary cholangitis. It was reported that there is no difference in prognosis between patients with HCC who undergo RFA and patients with
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
